Valion Bio, Inc. · NASDAQ:VBIO
Valion Bio — Tivic Health Systems — Investor Presentation (January 2026)
18 slides from Valion Bio's investor presentation, Jan 20, 2026
Slide 1: Harnessing the immune system to save lives and improve clinical outcomes
Nasdaq: TIVC | www.tivichealth.com ® ir@tivichealth.com – January 2026 – Jennifer Ernst, CEO, Tivic Health Harnessing the immune system to save lives and improve clinical outcomes • Late - stage, highly de - risked assets • Competitively differentiated treatments for radiation damage, oncology, and
Slide 2: Safe Harbor
Nasdaq: TIVC | www.tivichealth.com Slide # 2 Safe Harbor This presentation contains forward - looking statements . All statements other than statements of historical facts contained in this presentation may be forward - looking statements . Statements regarding our future results of operations and f
Slide 3: Experienced Management Team / Company Facts
Nasdaq: TIVC | www.tivichealth.com Experienced Management Team Company Facts Late - stage biologics Founded: 2016 IPO: 2021 Pivot: 2025 ~50 Employees Integrated manufacturing Nasdaq: TIVC
Slide 4: TLR5 Agonist Portfolio
Nasdaq: TIVC | www.tivichealth.com TLR5 Agonist Portfolio • Tivic secured worldwide exclusive rights in 2025 • Two recombinant proteins counteract radiation effects • Entolimod for acute syndromes – Late Phase III • Entolasta for chronic syndromes – Pre - clinical • $140M of prior investment, 40+ hu
Slide 5: Clinical Pipeline
Nasdaq: TIVC | www.tivichealth.com January 2026 Clinical Pipeline Slide # 5 Commercial Phase III Phase II IIA IIB Phase I Pre - clinical Discovery Acute Radiation Syndrome MCM Entolimod Acute Neutropenia Oncology Thrombocytopenia Immunosenescense General Mucositis Adjunct to Cellular Therapies Chron
Slide 6: The Radiation Issue
The Radiation Issue Ionizing radiation destroys fast - growing cells
Slide 7: 40+ Studies = Well Characterized Mechanism of Action
Nasdaq: TIVC | www.tivichealth.com Slide # 7 40+ Studies = Well Characterized Mechanism of Action Hemopoietic Damage GI Tract Damage • Platelet & Neutrophil Stimulator • GI and Hemopoetic Protective & Regenerative Properties • Rapid Onset of Action • Excellent Safety Profile • No Dose - Limiting Tox
Slide 8: $9.4B+ Existing Market, under attack from biosimilars
Nasdaq: TIVC | www.tivichealth.com Slide # 8 $9.4B+ Existing Market, under attack from biosimilars GI Tract Damage GI Tract Damage Hemopoietic Damage Current SOC New Class: TLR5 (Entolimod) Current SOC: G - CSF drugs Hemopoietic & GI Tract Hemopoietic Only Mitigates, Protects, Regenerates Mitigation
Slide 9: Entolimod could renew market leadership
Nasdaq: TIVC | www.tivichealth.com Slide # 9 Entolimod could renew market leadership Hemopoietic Damage GI Tract Damage New Class: TLR5 (Entolimod) Current SOC: G - CSF drugs Hemopoietic & GI Tract Hemopoietic Only Mitigates, Protects, Regenerates Mitigation Only Trials conducted with no supportive
Slide 10: Highly Differentiated Results
Nasdaq: TIVC | www.tivichealth.com Slide # 10 10 Highly Differentiated Results
Slide 11: Competitive Landscape
Nasdaq: TIVC | www.tivichealth.com Slide # 11 Competitive Landscape Leukine Nplate Neulasta Neupogen Entolimod ✓ ✓ ✓ ✓ ✓ Therapeutic - - - - ✓ Prophylactic - - - - ✓ Regenerative ✓ - ✓ ✓ ✓ Hemopoietic: Neutrophils - ✓ - - ✓ Hemopoietic: Platelets - - - - ✓ Gastrointestinal Repair Neupogen, Neulasta,
Slide 12: Commercialization Milestones Ahead for ARS
Nasdaq: TIVC | www.tivichealth.com Complete Engineering Scale - up Tests Commercialization Milestones Ahead for ARS Supports all other product candidates Scale - up manufacturing tests First cGMP Production Lot (<6 months) * Milestones are based on standard regulatory processes for biologic drugs. T
Slide 13: From ARS to Oncology
Nasdaq: TIVC | www.tivichealth.com From ARS to Oncology • Engagements in progress with US Agencies • Demonstrated unique therapeutic value • 3x increase in survival rate for ARS • Secured production capacity • International stockpile opportunities Slide # 13 Acute Radiation Syndrome
Slide 14: From ARS to Oncology: the Billion Dollar Move
Nasdaq: TIVC | www.tivichealth.com From ARS to Oncology: the Billion Dollar Move Entolimod is a first - in - class host - protection platform • Clinical work in ARS offers strong foundation in oncology Based on mechanism of action, Entolimod could: • Reduce severe treatment - limiting toxicities • P
Slide 15: The problem
Nasdaq: TIVC | www.tivichealth.com The problem • Radiation toxicity remains the primary limiter in cancer treatment • Severe radiation side effects drive • Hospitalizations • Treatment interruptions • Compliance • Underperformance of premium therapies (e.g. cell therapies) • Radiation toxicity is un
Slide 16: Entolimod as host protection
Nasdaq: TIVC | www.tivichealth.com Entolimod as host protection • Entolimod activates protective pathways of the innate immune system • Supports: • Neutrophil, platelet and GI endothelial recovery • Bone marrow regeneration • GI crypt preservation and regeneration • Our goal is to enable patients to
Slide 17: Recent News: Velocity Bioworks – a Tivic Subsidiary
Nasdaq: TIVC | www.tivichealth.com Recent News: Velocity Bioworks – a Tivic Subsidiary • Newly created CDMO subsidiary Slide # 17 An integrated CDMO focused on speed to clinic Guarantees Tivic access to CMC and cGMP manufacturing Accelerates time - to - market Accelerates new formulations and doses
Slide 18: Harnessing the immune system to save lives and improve clinical outcomes
Nasdaq: TIVC | www.tivichealth.com ® ir@tivichealth.com – January 2026 – Jennifer Ernst, CEO, Tivic Health Harnessing the immune system to save lives and improve clinical outcomes • Late - stage, highly de - risked assets • Competitively differentiated treatments for radiation damage, oncology, and
Tivic Health Systems — Investor Presentation (January 2026) on 6ix